However, the Q2 split of US market sales is now more like 75 percent Incivek®, 25 percent Victrelis®. Presumably, as the colder weather months of 2012 arrive, the Incivek sales will accelerate, again.
See the Vertex SEC Form 8-K:
. . . .Full-Year Incivek Revenues: Vertex today revised guidance for full-year 2012 Incivek net revenues. The company expects full-year 2012 net revenues to be in the range of $1.1 billion to $1.25 billion. The revised guidance reflects the recent downward trend in the number of patients initiating treatment within the hepatitis C market. . . .
[Incivek sales were expected to range from $1.5 billion to $1.7 billion, as of February 2, 2012. . . .]
Still a very strong quarterly performance — by Vertex. Up 6% on the NASDAQ.